1. Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability
- Author
-
Jostein Dahle, Jørgen Borrebæk, Roy H. Larsen, Cecilie Krogh, Miriam H. Valan, Katrine B. Melhus, and Øyvind S. Bruland
- Subjects
Cancer Research ,Immunoconjugates ,medicine.drug_class ,Monoclonal antibody ,Heterocyclic Compounds, 1-Ring ,Drug Stability ,Trastuzumab ,Cell Line, Tumor ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Antigens ,Pharmacology ,CD20 ,biology ,Chemistry ,Thorium ,Antibodies, Monoclonal ,General Medicine ,Antigen binding ,Molecular biology ,Oncology ,biology.protein ,Rituximab ,Bifunctional chelator ,Indicators and Reagents ,Fetal bovine serum ,medicine.drug - Abstract
In this study, the feasibility of constructing radioimmunoconjugates by using the novel therapeutic candidate alpha-emitter, (227)Th, was evaluated. By use of the bifunctional chelator, p-SCN-benzyl-DOTA, (227)Th was conjugated to the two monoclonal antibodies, rituximab and trastuzumab. Their stability in 80% fetal bovine serum at 37 degrees C was measured. The immunoreactive fractions were determined by using CD20- and HER/2-positive cells, respectively. The overall labeling yield spanned from 6% to 17%. The radioimmunoconjugates demonstrated a relevant stability in serum and showed appropriate antigen-binding abilities.
- Published
- 2007